Reply to: Expanding the Spectrum of Primary Cutaneous Carcinoma With BRD3-NUTM1 Fusion
Am J Surg Pathol
.
2021 Nov 1;45(11):1584-1586.
doi: 10.1097/PAS.0000000000001796.
Authors
Thibault Kervarrec
1
2
3
,
Florent Amatore
4
5
,
Daniel Pissaloux
6
7
,
Sandrine Paindavoine
6
,
Elodie Legrand
6
,
Jacqueline Lehmann-Che
8
9
,
Maxime Battistella
1
8
10
,
Nicolas Macagno
1
11
12
6
Affiliations
1
CARADERM, French Network of Rare Cutaneous Cancer.
2
Department of Pathology, Trousseau University Hospital.
3
INSERM U1282, Tours University Tours.
4
Department of Dermatology, APHM Nord University Hospital.
5
CNRS U7258, INSERM U1068 CRCM.
6
Department of Pathology, Center Léon Bérard.
7
INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, Lyon University Lyon.
8
INSERM U976, HIPI, Paris University.
9
Molecular Oncology Unit, Hospital Saint-Louis, AP-HP.
10
Department of Pathology, Hospital Saint-Louis, Paris, France.
11
INSERM U1251, MMG, Aix-Marseille University.
12
Department of Pathology, APHM Timone University Hospital, Marseille.
PMID:
34469332
DOI:
10.1097/PAS.0000000000001796
No abstract available
Publication types
Letter
Comment
MeSH terms
Carcinoma*
Humans
Nuclear Proteins / genetics
Transcription Factors* / genetics
Substances
BRD3 protein, human
Nuclear Proteins
Transcription Factors